Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Serum Vitamin D Level and Rheumatoid Arthritis Disease Activity: Review and Meta-Analysis

  • Jin Lin,

    Affiliation Department of Rheumatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

  • Jian Liu,

    Affiliation Department of Rheumatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China

  • Michael L. Davies,

    Affiliation Clinical Immunology Laboratory, Department of Microbiology and Immunology, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America

  • Weiqian Chen

    Affiliation Department of Rheumatology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China



The evidence from epidemiological studies concerning the relationship between serum vitamin D concentrations and rheumatoid arthritis (RA) is inconsistent. This meta-analysis is aimed at determining the magnitude of the correlation between this common autoimmune disease and vitamin D, an important nutrient known to dampen adaptive immune responses.


Through multiple search strategies, relevant literature was identified and evaluated for quality before May 16 2015. Data extracted from eligible studies was synthesized to calculate pooled correlation coefficient (r), mean difference (MD) and odds ratio (OR). The Venice criteria were applied to assess the credibility of the evidence for each statistically significant association.


A total of 24 reports involving 3489 patients were selected for analysis. RA patients had lower vitamin D levels than healthy controls (MD:-16.52 nmol/L, 95% confidence intervals [CI]:-18.85 to -14.19 nmol/L). There existed a negative relationship between serum 25-hydroxyvitamin D (25OHD) level and disease activity index, e.g. 25OHD vs. Disease Activity Score in 28 joints (DAS28): r = -0.13, 95% CI -0.16 to -0.09; 25OHD vs. C-reactive protein: r = -0.12, 95% CI -0.23 to -0.00. Additionally, latitude-stratified subgroup analysis yielded a relatively stronger negative correlation between 25OHD and DAS28 in low-latitude areas. This inverse relationship also appeared more significant in developing countries than in developed countries. No publication bias was detected.


RA patients had lower vitamin D values than healthy controls. There was a negative association between serum vitamin D and RA disease activity. However, more strictly controlled studies are needed to validate these findings.


Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by systemic features and joint involvement which affects 1% of the world’s adults [1]. It can lead to significant morbidity and mortality. Early diagnosis and proper treatment are crucial in decreasing the burden of this disease, but the pathogenesis and aetiology of RA remains unclear. Both genetic and nongenetic (e.g. environmental, infectious, hormonal) elements may be responsible for the prevalence of this disease [2]. Vitamin D might be one of the environmental factors relevant with RA [3]. There is a higher prevalence of osteoporosis in RA patients [4], and clinicians often supplement vitamin D together with calcium for this reason. Recent evidence demonstrates that vitamin D may correlate inversely with occurrence, development, disease activity and flare ups of RA [57]. The anti-inflammatory and immunomodulatory roles of vitamin D have gradually become apparent [8].

Vitamin D is a steroid hormone precursor that undergoes chemical conversion in the liver and kidney: the first reaction produces 25OHD, an objective indicator of vitamin D status, and the second produces the main bioactive form, 1,25-dihydroxyvitamin D (1,25(OH)2D) [9]. Vitamin D dampens the process of inflammation by influencing both innate and adaptive immune systems [10]. Dendritic cells and monocytes/macrophages belonging to the innate immune system express 1-alpha-hydroxylase to convert vitamin D to its active form 1,25(OH)2D and utilize it for autocrine and paracrine responses [10]. In the adaptive immune system, vitamin D downregulates expression of proteins involved in T helper type 1 (Th1) cell-driven autoimmunity, and participates in inhibition of antigen-presenting activity, antibody production, lymphocyte proliferation, dendritic cell differentiation and release of cytokines such as interleukin-2 (IL-2), IL-6, interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α) [1113]. In addition, vitamin D reinforces the development of monocytes into macrophages and then further influences their chemotaxis and cytokine expression [12]. Most autoimmune diseases, including inflammatory bowel disease, insulin-dependent diabetes mellitus, multiple sclerosis and rheumatoid arthritis, are Th1 cytokine-mediated disorders [14]. By dampening Th1 responses, vitamin D helps redirect the T cell response towards an immunosuppressive state.

There have been conflicting results regarding the correlation between RA and blood levels of 25OHD and 1,25(OH)2D [1518]. These contradictions may be due to differences in factors such as design, study population, analytical methods, testing tools and sample size. A meta-analysis performed three years ago showed that vitamin D intake was inversely associated with risk of RA [19]. However, within the population of RA patients, that study was unable to analyze correlations between serum vitamin D level and RA disease activity, due to huge heterogeneity and a limited number of studies. During the past three years, more research has been published in this area. This allowed us to summarize the increased wealth of evidence now available and carry out a meta-analysis to explore serum vitamin D values in RA patients and ask whether vitamin D concentrations can be clearly correlated with disease activity of RA.

Materials and Methods

Search Strategy

Two reviewers independently screened potentially relevant studies via a systematic search of the literature covering the following computerized bibliographic databases: Pubmed, EBSCO, Web of Science and the Cochrane Library. Publication language was limited to English only and the last search was performed on May 16 2015. The subject terms and keywords used in our searches are as follows: “vitamin D”, "25OHD", "1,25(OH)2D", "rheumatoid arthritis" and "RA". Furthermore, reference lists of the recruited articles were searched manually to find additional work.

Inclusion criteria were as follows: (1) Predefined RA definition. (2) Data on serum vitamin D values and RA in an adult (>18 years) population. (3) For duplicate publications including overlapping data sets, only the latest or the most comprehensive study was included. (4) Observational studies of all designs. As for exclusion criteria, patients with conditions that might influence vitamin D levels were excluded, along with unhealthy controls that could introduce potential bias. Comments, review articles, case reports, letters, editorials, proceedings and unpublished articles (abstracts only) were also excluded.

Data extraction

The following information was extracted independently by two reviewers (Jin Lin and Jian Liu) from each study: first author, publication year, country, diagnostic criteria, sample size, disease duration, age, sex, detection methods of vitamin D, vitamin D levels, and correlation coefficients between serum 25OHD (The major form of vitamin D considered in these studies) and disease activity index (Disease Activity Score in 28 joints [DAS28], serum C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]). One investigator (Jin Lin) compared extractions to ensure intercoder reliability and disagreement was coordinated by a third reviewer (Weiqian Chen) who did not take part in the original extraction.

Our study was approved by the ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.

Study quality assessment

We did this meta-analysis in compliance with Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines [20] and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines [21]. Two observers independently evaluated the methodological quality of the included studies using the Newcastle—Ottawa Scale(NOS) [22] for case-control or cohort studies and the Agency for Healthcare Research and Quality (AHRQ) for cross-sectional studies [23]. The Venice criteria were considered to assess the credibility of the evidence for each statistically significant association in this manuscript [24].

Statistical Analysis

In presenting the data on vitamin D values in RA patients and healthy controls, all incorporated studies used mean ± standard deviation (SD) except three [2527] which used mean ± standard errors of means (SEM), thus we transformed SEM to SD to maintain consistency [28]. For evaluating vitamin D deficiency in RA patients and healthy controls, we calculated the pooled OR with the Mantel-Haenszel method. Vitamin D deficiency was defined as 25OHD<50 nmol/l according to published papers [29, 30]. When referring to the association between vitamin D and RA disease activity, Pearson correlation test was applied in most of the included articles, and for others we converted the Spearman correlation coefficients into Pearson correlation coefficients in order to minimize statistical errors [31]. Standard errors of correlation coefficients were calculated with Formula 1 and Formula 2. The 95% confidence intervals (CI) of each correlation coefficient was calculated using a Fisher’s z transformation (Formula 3) using the generic inverse variance method, after which all the values were transformed back to the original correlation coefficient metric (Formula 4) [3234]. Formulas 1–4 are shown in S1 Fig.

Heterogeneity was assessed by using Cochran’s Q-statistic and inconsistency index (I2) test [35, 36]. An I2-value>50% or P value<0.05 suggested heterogeneity [37], and these data were calculated with DerSimonian & Laird random-effects models to accommodate diversity [38]. Otherwise, data were pooled with a fixed-effects model when there was no obvious heterogeneity [39].

We explored heterogeneity through a sequence of a priori secondary analyses. First, sensitivity analysis was conducted by excluding individual studies in turns for the purpose of discovering the potential influence of a single study on the final results. Second, Egger’s regression test was used to detect potential publication bias [39]. Third, we stratified the included studies according to measues of autoimmune disease activity (DAS28, ESR and CRP) to explicitly verify their relationship. Fourth, two subgroup analyses were made on the relationship between serum vitamin D levels and DAS28 based on latitude and economic status. Statistical difference between subgroups were calculated with the methods put forward by Snedecor, et al [40]. RevMan 5.3 software (Cochrane Library, Oxford, UK) and STATA 12.0 (Stata Corporation, TX, USA) were used for data acquisition and management.

Data processing details

Two studies [27, 41] measured 25OHD in the same population during two seasons. As patients tend to suffer greater vitamin D deficiency and more severe arthritis symptoms in winter [42], the summer data was extracted to reduce false positive rate, which was also in agreement with most selected studies. Two other articles contained two datasets each, and each dataset was treated independently [42, 43].

Key confounders such as age, sex were accurately adjusted.


Study characteristics

The study selection procedure is described in Fig 1. In the final analysis, two sets of studies with some results in common (Rossini [15] and Rossini [44]; Oelzner [45], Oelzner [46] and Oelzner [47]) were identified and the most comprehensive one in each set was singled out for our meta-analysis. Thus a total of 24 reports were enrolled. The eligible studies were published between 1998 and 2015 involving 3489 patients. Thirteen studies were performed in Asia, 5 in Europe, 4 in North America, 1 in South America and 1 in Africa. Most enrolled articles showed moderate to high quality on the basis of NOS scores. Fourteen studies were selected for analyzing differences of vitamin D values in RA patients and healthy controls. Six studies were employed to compare vitamin D deficiency rate in RA patients and healthy controls. Finally, we selected fifteen studies to investigate the relationship between serum vitamin D levels and severity of disease among RA patients. Table 1 shows the main features of the relevant studies.

Table 1. Characteristics of the included studies.

rD: correlation between Vitamin D and DAS28; rE: correlation between Vitamin D and ESR; rC: correlation between Vitamin D and CRP; A: DAS28≥2.6; B: DAS28<2.6; NG: not given; RIA: radio-immunoassay; CLIA: chemiluminescent immunoassay; HPLC: high-performance liquid chromatography; ELISA: enzyme-linked immunosorbent assay; LCMS/MS: liquid chromatography tandem mass spectrometry; US: United States; ACR: American College of Rheumatology; EULAR: European League Against Rheumatism.

Vitamin D values in RA patients

2148 RA patients and 1991 healthy controls were selected for this quantitative synthesis. The average 25OHD level in RA patients was 13.21 nmol/L less than that in controls (mean difference [MD] = -13.21 nmol/L, 95% CI = -22.03 to -4.39 nmol/L) which exhibited notable heterogeneity (I2 = 95%, P<0.001). After sensitivity analysis, removing Rossini, et al and Kostoglou-Athanassiou, et al [15, 26] (the only outliers) remarkably reduced this heterogeneity with little influence on the outcome (MD = -16.52 nmol/L, 95% CI = -18.85 to -14.19 nmol/L, I2 = 46%, P = 0.04) (Fig 2). The Venice criteria grade was BBA, which resulted in a characterization as moderate evidence.

Fig 2. Forest plot of serum vitamin D values in RA patients and healthy controls using continuous variance methods.

We further selected six studies to compare vitamin D deficiency rate using dichotomous variance methods and did not find a significant difference between RA patients and healthy controls (OR = 1.49, 95% CI = 0.87 to 2.54, I2 = 88%, P<0.001). Three studies [15, 48, 49] were considered homogeneous after a sensitivity analysis and were excluded; comparing the remaining three studies showed a pooled OR = 1.06, 95% CI = 0.8 to 1.4, I2 = 0%, P = 0.7 (Fig 3).

Fig 3. Forest plot of serum vitamin D values in RA patients and healthy controls using dichotomous variance methods.

Relationship between vitamin D and RA activity

We then specifically selected studies in which the association between serum vitamin D values and RA disease activity was presented with Pearson or Spearman correlation tests. The main outcome of this meta-analysis is summarized in Fig 4 and Table 2. All summary Fisher’s z scores were transformed back to r values as previously described. The pooled r for 25OHD compared to DAS28 (disease activity score in 28 joints) was -0.13 (95% CI -0.16 to -0.09, I2 = 46%, P = 0.02), producing a Venice criteria grade of ABA (Fig 4A). 25OHD was also inversely associated with serum CRP (r = -0.12, 95%CI -0.23 to -0.00, I2 = 0%, P = 0.74), producing a Venice criteria grade of BAA (Fig 4B). Both of these grades indicate moderately strong evidence for a correlation between increased 25OHD and reduced symptoms of RA disease. However, there was no significant correlation between 25OHD and erythrocyte sedimentation rate (r = -0.02, 95%CI -0.13 to 0.08, I2 = 0%, P = 0.52) (Fig 4C). Among these three analyses, the comparison of 25OHD to DAS28 had the most statistical power, as it incorporated 15 publications while the comparisons to CRP and ESR only incorporated 5 publications each.

Fig 4. Forest plots of disease activity and serum vitamin D levels in RA patients.

Summary of Fisher’s z tests with corresponding 95% confidence intervals for the relationship between: A) serum vitamin D levels and DAS28 scores; B) serum vitamin D levels and serum CRP levels; C) serum vitamin D levels and erythrocyte sedimentation rate.

Table 2. The main statistical results concerning vitamin D and RA disease activity.

F: fixed-effects model; N: the relationship between vitamin D and RA was not statistically significant, and therefore we did not assess Venice Criteria grade.

Finally, we conducted two subgroup analyses based on latitude and economic status of the locations where the studies were performed. The negative relation between vitamin D values and RA disease activity was more clearly displayed in low latitude areas as well as in developing countries. The results of the subgroup analyses and the Venice criteria grades are shown in Fig 5A and 5B and Table 3.

Fig 5. Forest plots of subgroup analysis focused on the relationship between serum vitamin D levels and disease activity scores in RA patients.

Summary of Fisher’s z scores with corresponding 95% confidence intervals for the relationship between serum vitam D levels and DAS28 scores: A) stratified according to latitude; B) stratified according to economic status.

Table 3. Subgroup analysis results.

F: fixed effects model; R: random effects model.

Publication bias and sensitivity analysis

Symmetrical funnel plots (S2 Fig) along with Egger’s regression test (Table 2) did not reveal any publication bias.

Further sensitivity analysis, by repeatedly reanalyzing the data after removing individual studies from the meta-analysis, demonstrated that no study was responsible for a disproportionate influence on the pooled estimates, indicating a statistically robust result of this analysis.


Through a comprehensive and quantitative meta-analysis, our results demonstrate that rheumatoid arthritis patients have lower vitamin D serum values than healthy controls, and that among RA patients there is a negative relationship between vitamin D serum values and RA disease activity. This meta-analysis follows two studies by independent groups that reported a significant inverse connection between serum 25OHD concentrations and DAS28 in patients with active RA (DAS28≥2.6) [42, 50]. However, Craig, et al [16] failed to discover a statistically significant association between 25OHD and DAS28 following multivariate adjustments in recent-onset rheumatoid arthritis patients. Cutolo, et al [27] found a remarkable negative correlation between 25OHD and DAS28 in summer only in southern European (Italian) patients and in winter in northern European (Estonian) patients, but no significant differences with respect to 25OHD values between Estonian and Italian RA patients and their controls. Attar, et al [51] discovered that 25OHD levels were only prominently lower in patients who poorly responded to therapy. To further investigate these links, we integrated a series of studies that included a considerable variety of disease durations, disease symptoms, and ethnicities, and we observed that the pooled correlations reached statistical significance. This is likely explained by the increased statistical power and resolution that meta-analysis makes possible via pooling the results of independent studies.

A systematic review published in 2010 [52] listed 7 studies evaluating vitamin D deficiency rate in RA patients compared with healthy controls. Two of these studies exhibited lower concentrations of vitamin D in RA, while the other five did not. However, this systematic review did not synthesize the data from each study to get an exact pooled estimate. Although our quantitative synthesis results did not find a significant statistical difference concerning the frequency of vitamin D deficiency (25OHD<50nmol/L) in RA patients and healthy controls, we did observe that 25OHD levels in RA patients are consistently lower than those in healthy control subjects. It can be inferred that low vitamin D levels may be associated with higher incidence of RA, as has already been mentioned by Song, et al [19].

Synovitis and pannus are the main pathological features of RA. CRP and ESR are non-specific inflammatory markers that have long been used for assessing systemic inflammation. DAS28 is a synthetically quantitative index which along with CRP and ESR can give a comprehensive picture of the inflammatory situations of RA patients [53]. In the current study, a considerable inverse association was observed between 25OHD levels and DAS28, as well as between 25OHD and CRP. However, the relationship between 25OHD and ESR was not as conclusive. This may be partly because CRP is a more direct measure of inflammation than ESR, and physiologically more sensitive to short-term changes, while ESR can continue to be elevated days after episodes of inflammation that have already resolved [53]. ESR is also influenced by many confounding factors such as temperature, age, gender, hematocrit and specimen handling technique; a normal population will have a greater variance in ESR values than CRP values, making it less likely that statistically significant ESR differences will be observed between groups [54]. Some experts have even proposed that CRP alone should be used as an alternative to ESR in the DAS28 calculation formula [55].

Subgroup analyses were implemented to further clarify the potential relationship between DAS28 and 25OHD. Strikingly, the latitude-stratified results demonstrated a stronger association in low-latitude areas. This may be explained by differences in duration of sun exposure and regional climates. For example, low-latitude areas tend to suffer more rain and the moist weather can give rise to greater arthritis pain which results in higher DAS28 scores. Subgroups classified by economic status similarly revealed a tighter relationship in developing countries. This may relate to differences in diet, hygiene, use of medications and vitamin supplements, or other factors; it has also been observed that RA is more common in wealthier countries but average RA activity is more severe in less developed countries [56, 57]. Increased correlation between vitamin D levels and RA in less wealthy countries may also stem from increased likelihood of exposure to environmental pollutants and infections, which could have synergistic effects exacerbating the effect of vitamin D deficiency [58].

The development of RA involves a diverse range of environmental and genetic factors. Indeed, studies a decade ago using murine models showed that vitamin D can prevent the incidence and progression of collagen-induced arthritis [59]. Other data have suggested that vitamin D receptor (VDR) agonists can suppress the severity of established collagen-induced arthritis [60]. VDR gene polymorphisms may influence vitamin D function, as well as its serum levels, and a recent meta-analysis displayed a significant contribution of TaqI and FokI VDR polymorphisms to RA risk [61]. Meanwhile, long-term use of vitamin D supplements can upregulate VDR signaling [62]. VDR can be found at high levels on immune system cells like dendritic cells, macrophages, and activated T and B lymphocytes, suggesting that the immunoregulatory action of vitamin D acts through many mechanisms [63]. Through binding VDR, vitamin D can suppress proinflammatory processes by inhibiting the enhanced activity of immune cells that participate in an adaptive autoimmune response. It appears to regulate immune homeostasis through reinforcing the innate response but impeding adaptive immunity. Vitamin D can also shift the balance from Th1 to Th2 and T regulatory cells [52], inhibiting the proliferation of Th1 cells that can exacerbate inflammation, generate bone loss and eventually lead to osteopenia and osteoporosis [64]. However, it has also been suggested that serum 25OHD levels may decrease in the acute-phase response, suggesting that low concentrations may be the result of high-grade systemic inflammation rather than a cause of inflammation [65]. Despite that, vitamin D concentrations were not affected when other phase reactants were reduced in rituximab- or adalimumab-treated RA patients [66, 67]. This cause-and-effect relationship may be elucidated by further research.

It is also worth noting that serum 25OHD concentrations did not correlate with disease activity in RA patients who were supplemented with physiological doses of vitamin D over a short period [7, 41, 68]. Therefore, investigating the optimal vitamin D cutoff point for predicting RA disease activity as well as for exerting its therapeutic functions would be clinically helpful.

The main active form of vitamin D, 1,25(OH)2D is responsible for most, if not all, of the immunoregulatory effects of vitamin D [69]. Oelzner, et al [4547] reported a sequence of studies on the negative relevance between 1,25(OH)2D and RA disease activity. A randomised controlled trial operated by Gopinath, et al emphasized the pain relief action of 1,25(OH)2D in Disease Modifying Anti Rheumatic Drugs (DMARD)-naive RA [70]. However, most articles described in our manuscript did not consider 1,25(OH)2D in outcomes and we thus could not include it in our meta-analysis because of insufficient data.

As more and more research supports the idea of vitamin D as a regulatory factor in human immunity, correction of vitamin D deficiency may become a standard element of immunoregulation strategies in some autoimmune diseases. For example, Kim, et al [71] proposed that antirheumatic drugs combined with vitamin D should be recommended for RA. Vitamin D supplementation can prevent and treat osteoporosis at the same time, enhancing its possible effect on disease activity [72].

Several limitations exist in our analysis. First, the number of recruited patients in some studies was relatively small. However, stable results from sensitivity analysis, and the complete analysis of 24 different studies including a total of 3489 patients, strengthen our conclusion. Second, it could be suggested that due to variabilities in the way vitamin D was measured, pooling of the data was unsuitable. Nevertheless, the extracted information was consistent in terms of correlation coefficient, and our meta-analysis results exhibited no significant heterogeneity. Furthermore, these incorporated studies all came from institutions with high levels of expertise to conduct this type of experiment, such that high quality was very likely in most circumstances despite the variations. Third, despite our attempts to ensure inclusion of all relevant publications, and the lack of publication bias as illustrated by symmetrical funnel plots, we were unable to obtain unpublished or non-English research, and our pooled estimates might be overestimated if only significant or positive results have been reported. Fourth, meta-analyses of observational studies cannot be used for establishing a causative link. There has been extensive argument about whether researchers so far have adequately accounted for the potential confounding variables. However, even a randomized controlled trial is unlikely to conquer the many measurement challenges inherent to this topic. Similarly, the limitations of our analysis are also present in the original studies. For example, 25OHD levels can increase markedly with even transient exposure to ultraviolet B, and then persist for 2–3 weeks in the serum because of the long half-life of 25OHD compared to many serum biomarkers [73]. Hence the measurement of 25OHD with unawareness of disparities in sun exposure can introduce bias. Fifth, we are unable to use these results to suggest specific treatment strategies due to limited information.


In conclusion, our meta-analysis indicates that serum vitamin D levels are lower in rheumatoid arthritis patients and are inversely associated with RA disease activity, particularly in low-latitude and developing nations. Further studies with larger sample sizes and more standardized, unbiased methods are required to elucidate a causal role of vitamin D in RA and thus to bring about new approaches for prevention and treatment of this disease.

Supporting Information

S2 Fig. Funnel plots of results.

A. Funnel plot for vitamin D values in RA patients vs. healthy controls; B. Funnel plot for vitamin D deficiency in RA patients vs. healthy controls; C. Funnel plot for serum vitamin D vs. RA disease activity score (DAS28); D. Funnel plot for serum vitamin D vs. serum C-reactive protein; E. Funnel plot for serum vitamin D vs. erythrocyte sedimentation rate.


Author Contributions

Conceived and designed the experiments: J. Lin J. Liu WC. Performed the experiments: J. Lin J. Liu WC. Analyzed the data: J. Lin J. Liu WC. Contributed reagents/materials/analysis tools: J. Lin J. Liu. Wrote the paper: J. Lin J. Liu MLD WC.


  1. 1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmunity reviews. 2005;4(3):130–6. pmid:15823498
  2. 2. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B. Vitamin D in rheumatoid arthritis. Autoimmunity reviews. 2007;7(1):59–64. pmid:17967727.
  3. 3. Azzeh FS. Relationship between vitamin D and rheumatoid arthritis disease. Pakistan Journal of Nutrition. 2012;11(3):293–300.
  4. 4. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. The New England journal of medicine. 2011;365(23):2205–19. Epub 2011/12/14. pmid:22150039.
  5. 5. Dehghan A, Rahimpour S, Soleymani-Salehabadi H, Owlia MB. Role of vitamin D in flare ups of rheumatoid arthritis. Zeitschrift fur Rheumatologie. 2014;73(5):461–4. pmid:24352479.
  6. 6. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Current opinion in rheumatology. 2013;25(2):184–91. pmid:23370372.
  7. 7. Braun-Moscovici Y, Toledano K, Markovits D, Rozin A, Nahir AM, Balbir-Gurman A. Vitamin D level: is it related to disease activity in inflammatory joint disease? Rheumatology international. 2011;31(4):493–9. pmid:20033415.
  8. 8. Neve A, Corrado A, Cantatore FP. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clinical and experimental medicine. 2014;14(3):275–83. pmid:23824148.
  9. 9. Atherton K, Berry DJ, Parsons T, Macfarlane GJ, Power C, Hypponen E. Vitamin D and chronic widespread pain in a white middle-aged British population: evidence from a cross-sectional population survey. Annals of the rheumatic diseases. 2009;68(6):817–22. pmid:18697776.
  10. 10. Hewison M. An update on vitamin D and human immunity. Clinical endocrinology. 2012;76(3):315–25. pmid:21995874
  11. 11. Szodoray P, Nakken B, Gaal J, Jonsson R, Szegedi A, Zold E, et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol. 2008;68(3):261–9. pmid:18510590.
  12. 12. Maruotti N, Cantatore FP. Vitamin D and the immune system. J Rheumatol. 2010;37(3):491–5. Epub 2010/01/19. pmid:20080911.
  13. 13. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. The Journal of steroid biochemistry and molecular biology. 2005;97(1–2):93–101. pmid:16046118.
  14. 14. Zold E, Barta Z, Bodolay E. Vitamin D deficiency and connective tissue disease. Vitamins and hormones. 2010;86:261–86.
  15. 15. Rossini M, Maddali Bongi S, La Montagna G, Minisola G, Malavolta N, Bernini L, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis research & therapy. 2010;12(6):R216. pmid:21114806; PubMed Central PMCID: PMC3046526.
  16. 16. Craig SM, Yu F, Curtis JR, Alarcon GS, Conn DL, Jonas B, et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol. 2010;37(2):275–81. pmid:20032100; PubMed Central PMCID: PMC3133625.
  17. 17. Skaaby T, Husemoen LL, Thuesen BH, Linneberg A. Prospective population-based study of the association between vitamin D status and incidence of autoimmune disease. Endocrine. 2015. pmid:25666936.
  18. 18. Racovan M, Walitt B, Collins CE, Pettinger M, Parks CG, Shikany JM, et al. Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women's Health Initiative Calcium plus Vitamin D trial. Rheumatology international. 2012;32(12):3823–30. pmid:22190273.
  19. 19. Song GG, Bae SC, Lee YH. Association between vitamin D intake and the risk of rheumatoid arthritis: a meta-analysis. Clinical rheumatology. 2012;31(12):1733–9. pmid:22941259.
  20. 20. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama. 2000;283(15):2008–12. pmid:10789670
  21. 21. Panic N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PloS one. 2013;8(12):e83138. pmid:24386151
  22. 22. Wells G, Shea B, O’connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.Ottawa Health Research Institute http://wwwohrica/programs/clinical_epidemiology/oxford.
  23. 23. Rostom A, Dubé C, Cranney A, Saloojee N, Sy R, Garritty C, et al. Celiac disease: Agency for Healthcare Research and Quality; 2004.
  24. 24. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. International journal of epidemiology. 2008;37(1):120–32. pmid:17898028.
  25. 25. Brance ML, Brun LR, Lioi S, Sanchez A, Abdala M, Oliveri B. Vitamin D levels and bone mass in rheumatoid arthritis. Rheumatology international. 2015;35(3):499–505. pmid:24980067.
  26. 26. Kostoglou-Athanassiou I, Athanassiou P, Lyraki A, Raftakis I, Antoniadis C. Vitamin D and rheumatoid arthritis. Therapeutic advances in endocrinology and metabolism. 2012;3(6):181–7. pmid:23323190
  27. 27. Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, et al. Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol. 2006;24(6):702–4. Epub 2007/01/09. pmid:17207389.
  28. 28. Cai G, Wang L, Fan D, Xin L, Liu L, Hu Y, et al. Vitamin D in ankylosing spondylitis: review and meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2015;438:316–22. pmid:25199851.
  29. 29. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2011;96(7):1911–30. Epub 2011/06/08. pmid:21646368.
  30. 30. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM. Vitamin D status as an international issue: national surveys and the problem of standardization. Scandinavian journal of clinical and laboratory investigation Supplementum. 2012;243:32–40. Epub 2012/06/08. pmid:22536760.
  31. 31. Rupinski MT, Dunlap WP. Approximating Pearson product-moment correlations from Kendall's tau and Spearman's rho. Educational and psychological measurement. 1996;56(3):419–29.
  32. 32. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis: John Wiley & Sons; 2011.
  33. 33. Chalkidou A, Landau DB, Odell EW, Cornelius VR, O'Doherty MJ, Marsden PK. Correlation between Ki-67 immunohistochemistry and 18F-fluorothymidine uptake in patients with cancer: A systematic review and meta-analysis. European journal of cancer. 2012;48(18):3499–513. pmid:22658807.
  34. 34. Tsiligianni I, Kocks J, Tzanakis N, Siafakas N, van der Molen T. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Primary care respiratory journal: journal of the General Practice Airways Group. 2011;20(3):257–68. pmid:21472192.
  35. 35. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Annals of internal medicine. 2008;149(12):889–97. pmid:19075208
  36. 36. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC medical research methodology. 2006;6(1):31.
  37. 37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ: British Medical Journal. 2003;327(7414):557. pmid:12958120
  38. 38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986;7(3):177–88. Epub 1986/09/01. pmid:3802833.
  39. 39. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34. pmid:9310563
  40. 40. GW S, WG C. Statistical methods. Iowa State University Press. 1980,:185–8.
  41. 41. Yazmalar L, Ediz L, Alpayci M, Hiz O, Toprak M, Tekeoglu I. Seasonal disease activity and serum vitamin D levels in rheumatoid arthritis, ankylosing spondylitis and osteoarthritis. African health sciences. 2013;13(1):47–55. Epub 2013/05/10. pmid:23658567; PubMed Central PMCID: PMCPmc3645084.
  42. 42. Haque UJ, Bartlett SJ. Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol. 2010;28(5):745–7. Epub 2010/10/05. pmid:20883640.
  43. 43. Hiraki LT, Arkema EV, Cui J, Malspeis S, Costenbader KH, Karlson EW. Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis. Rheumatology. 2014;53(12):2243–8. pmid:25065001; PubMed Central PMCID: PMC4241892.
  44. 44. Rossini M, D'Avola G, Muratore M, Malavolta N, Silveri F, Bianchi G, et al. Regional differences of vitamin D deficiency in rheumatoid arthritis patients in Italy. Reumatismo. 2013;65(3):113–20. Epub 2013/07/26. pmid:23884026.
  45. 45. Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcified tissue international. 1998;62(3):193–8. Epub 1998/03/21. pmid:9501950.
  46. 46. Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology. 1999;38(9):841–7. Epub 1999/10/09. pmid:10515645.
  47. 47. Oelzner P, Lehmann G, Eidner T, Franke S, Muller A, Wolf G, et al. Hypercalcemia in rheumatoid arthritis: relationship with disease activity and bone metabolism. Rheumatology international. 2006;26(10):908–15. pmid:16404562.
  48. 48. Gheita TA, Sayed S, Gheita HA, Kenawy SA. Vitamin D status in rheumatoid arthritis patients: relation to clinical manifestations, disease activity, quality of life and fibromyalgia syndrome. Int J Rheum Dis. 2014. Epub 2014/10/08. pmid:25291242.
  49. 49. Hong Q, Xu J, Xu S, Lian L, Zhang M, Ding C. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology. 2014;53(11):1994–2001. pmid:24907153.
  50. 50. Raczkiewicz A, Kisiel B, Kulig M, Tlustochowicz W. Vitamin d status and its association with quality of life, physical activity, and disease activity in rheumatoid arthritis patients. Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases. 2015;21(3):126–30. pmid:25807091.
  51. 51. Attar SM. Vitamin D deficiency in rheumatoid arthritis. Prevalence and association with disease activity in Western Saudi Arabia. Saudi medical journal. 2012;33(5):520–5. Epub 2012/05/17. pmid:22588813.
  52. 52. Kriegel MA, Manson JE, Costenbader KH. Does vitamin D affect risk of developing autoimmune disease?: a systematic review. Seminars in arthritis and rheumatism. 2011;40(6):512–31.e8. Epub 2010/11/05. pmid:21047669; PubMed Central PMCID: PMCPmc3098920.
  53. 53. van Riel PL. The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28). Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-65–74. Epub 2014/11/05. pmid:25365092.
  54. 54. Ng T. Erythrocyte sedimentation rate, plasma viscosity and C-reactive protein in clinical practice. British journal of hospital medicine. 1997;58(10):521–3. Epub 1999/04/08. pmid:10193457.
  55. 55. Fransen J, Welsing P, De Keijzer R, Van Riel P, editors. Development and validation of the DAS28 using CRP. Annals of the rheumatic diseases; 2003: BMJ PUBLISHING GROUP BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND.
  56. 56. Putrik P, Ramiro S, Hifinger M, Keszei AP, Hmamouchi I, Dougados M, et al. In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study. Annals of the rheumatic diseases. 2015. Epub 2015/09/01. pmid:26314921.
  57. 57. Okada H, Kuhn C, Feillet H, Bach JF. The 'hygiene hypothesis' for autoimmune and allergic diseases: an update. Clinical and experimental immunology. 2010;160(1):1–9. Epub 2010/04/27. pmid:20415844; PubMed Central PMCID: PMCPMC2841828.
  58. 58. Edwards CJ, Cooper C. Early environmental factors and rheumatoid arthritis. Clinical and experimental immunology. 2006;143(1):1–5. Epub 2005/12/22. pmid:16367927; PubMed Central PMCID: PMCPMC1809562.
  59. 59. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. The Journal of nutrition. 1998;128(1):68–72. Epub 1998/01/31. pmid:9430604.
  60. 60. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cellular immunology. 2005;233(2):115–24. Epub 2005/06/07. pmid:15936743.
  61. 61. Tizaoui K, Hamzaoui K. Association between VDR polymorphisms and rheumatoid arthritis disease: Systematic review and updated meta-analysis of case-control studies. Immunobiology. 2014. pmid:25577294.
  62. 62. Ceglia L, Niramitmahapanya S, da Silva Morais M, Rivas DA, Harris SS, Bischoff-Ferrari H, et al. A randomized study on the effect of vitamin D(3) supplementation on skeletal muscle morphology and vitamin D receptor concentration in older women. The Journal of clinical endocrinology and metabolism. 2013;98(12):E1927–35. Epub 2013/10/11. pmid:24108316; PubMed Central PMCID: PMCPmc3849671.
  63. 63. Guillot X, Semerano L, Saidenberg-Kermanac'h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint, bone, spine: revue du rhumatisme. 2010;77(6):552–7. pmid:21067953.
  64. 64. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Annals of the rheumatic diseases. 2007;66(9):1137–42. pmid:17557889
  65. 65. Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DS, et al. The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. The American journal of clinical nutrition. 2011;93(5):1006–11. Epub 2011/03/18. pmid:21411617.
  66. 66. Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S. Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis. Biologics: targets & therapy. 2012;6:31–5. Epub 2012/02/23. pmid:22355257; PubMed Central PMCID: PMCPmc3280863.
  67. 67. Welsh P, Peters MJ, McInnes IB, Lems WF, Lips PT, McKellar G, et al. Vitamin D deficiency is common in patients with RA and linked to disease activity, but circulating levels are unaffected by TNFalpha blockade: results from a prospective cohort study. Annals of the rheumatic diseases. 2011;70(6):1165–7. Epub 2010/11/05. pmid:21047908.
  68. 68. Sahebari M, Mirfeizi Z, Rezaieyazdi Z, Rafatpanah H, Goshyeshi L. 25(OH) vitamin D serum values and rheumatoid arthritis disease activity (DA S28 ESR). Caspian journal of internal medicine. 2014;5(3):148–55. Epub 2014/09/10. pmid:25202442; PubMed Central PMCID: PMCPmc4143736.
  69. 69. Hewison M. Vitamin D and the immune system: new perspectives on an old theme. Rheumatic diseases clinics of North America. 2012;38(1):125–39. Epub 2012/04/25. pmid:22525848.
  70. 70. Gopinath K, Danda D. Supplementation of 1,25 dihydroxy vitamin D3 in patients with treatment naive early rheumatoid arthritis: a randomised controlled trial. Int J Rheum Dis. 2011;14(4):332–9. Epub 2011/10/19. pmid:22004229.
  71. 71. Kim TH, Choi SJ, Lee YH, Song GG, Ji JD. Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis. Medical hypotheses. 2012;79(6):757–60. Epub 2012/09/13. pmid:22967804.
  72. 72. Varenna M, Manara M, Cantatore FP, Del Puente A, Di Munno O, Malavolta N, et al. Determinants and effects of vitamin D supplementation on serum 25-hydroxy-vitamin D levels in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(5):714–9. Epub 2012/07/07. pmid:22766134.
  73. 73. Zhao S, Duffield SJ, Moots RJ, Goodson NJ. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology. 2014;53(9):1595–603. pmid:24706990.
  74. 74. Atwa MA, Balata MG, Hussein AM, Abdelrahman NI, Elminshawy HH. Serum 25-hydroxyvitamin D concentration in patients with psoriasis and rheumatoid arthritis and its association with disease activity and serum tumor necrosis factor-alpha. Saudi medical journal. 2013;34(8):806–13. Epub 2013/08/27. pmid:23974451.
  75. 75. Baykal T, Senel K, Alp F, Erdal A, Ugur M. Is there an association between serum 25-hydroxyvitamin d concentrations and disease activity in rheumatoid arthritis? Bratislava Medical Journal. 2013;113(10):610–1.
  76. 76. Sabbagh Z, Markland J, Vatanparast H. Vitamin D status is associated with disease activity among rheumatology outpatients. Nutrients. 2013;5(7):2268–75. pmid:23803739; PubMed Central PMCID: PMC3738972.
  77. 77. Baker JF, Baker DG, Toedter G, Shults J, Von Feldt JM, Leonard MB. Associations between vitamin D, disease activity, and clinical response to therapy in rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(5):658–64. Epub 2012/07/11. pmid:22776409.
  78. 78. Chen J, Liu W, Lin Q, Chen L, Yin J, Huang H. Vitamin D deficiency and low bone mineral density in native Chinese rheumatoid arthritis patients. Int J Rheum Dis. 2014;17(1):66–70. Epub 2013/10/18. pmid:24131858.
  79. 79. Matsumoto Y, Sugioka Y, Tada M, Okano T, Mamoto K, Inui K, et al. Relationships between serum 25-hydroxycalciferol, vitamin D intake and disease activity in patients with rheumatoid arthritis—TOMORROW study. Modern rheumatology / the Japan Rheumatism Association. 2015;25(2):246–50. pmid:25211403.
  80. 80. Azzeh FS, Kensara OA. Vitamin D Is a Good Marker for Disease Activity of Rheumatoid Arthritis Disease. Disease markers. 2015;2015:260725. pmid:26063950; PubMed Central PMCID: PMC4441987.
  81. 81. Sharma R, Saigal R, Goyal L, Mital P, Yadav RN, Meena PD, et al. Estimation of vitamin D levels in rheumatoid arthritis patients and its correlation with the disease activity. The Journal of the Association of Physicians of India. 2014;62(8):678–81. Epub 2015/04/11. pmid:25856934.
  82. 82. Turhanoglu AD, Guler H, Yonden Z, Aslan F, Mansuroglu A, Ozer C. The relationship between vitamin D and disease activity and functional health status in rheumatoid arthritis. Rheumatology international. 2011;31(7):911–4. pmid:20300755.
  83. 83. Heidari B, Hajian-Tilaki K, Heidari P. The status of serum vitamin D in patients with rheumatoid arthritis and undifferentiated inflammatory arthritis compared with controls. Rheumatology international. 2012;32(4):991–5. pmid:21246367.